Company news

Alvotech news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

October 28, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

October 28, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

October 20, 2026

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

October 20, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

October 14, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

October 14, 2026

Alvotech: Half yearly financial audit reports reviews 2026 10 07 13h09m51 (1)

October 12, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

October 6, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

October 6, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

October 5, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

October 5, 2026

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

August 31, 2026

Alvotech to present at upcoming investor conferences in September

August 27, 2026

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

August 21, 2026

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

August 19, 2026

Alvotech announces successful closure of FDA inspection of manufacturing facility

July 29, 2026

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

June 18, 2026

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

June 15, 2026

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

June 15, 2026

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

June 8, 2026

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

June 4, 2026

Alvotech to present at upcoming investor conferences in June

June 2, 2026

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

May 31, 2026

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 11, 2026

Alvotech Q1 2026 Financial Results

May 6, 2026

Alvotech Announces a Change in its Executive Team

April 30, 2026

Alvotech to Report Financial Results for the First Quarter of 2026

April 24, 2026

Alvotech Publishes 2025 Annual Report

March 29, 2026

Alvotech Files Annual Report with the SEC

March 29, 2026

Alvotech files Annual Report with the SEC

March 29, 2026

Alvotech Q4 2025 and Full Year 2025 Financial Results

March 17, 2026

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

March 3, 2026

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

February 4, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

February 1, 2026

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

January 28, 2026

Correction: Transactions of Managers and Closely Associated Persons

January 6, 2026

Alvotech announces planned CEO succession and leadership transition

January 6, 2026

Transactions of Managers and Closely Associated Persons

January 5, 2026

Alvotech Secures Term Loan Facility of USD 100 Million

December 30, 2025

Alvotech’s Financial Calendar for 2026

December 21, 2025

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

December 21, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

December 18, 2025

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

December 16, 2025

Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance

December 15, 2025

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

November 23, 2025

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

November 19, 2025

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

November 11, 2025

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

November 9, 2025

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

November 9, 2025

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

November 5, 2025

Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.